WallStSmart
NDRA

ENDRA Life Sciences Inc

NASDAQ: NDRA · HEALTHCARE · DIAGNOSTICS & RESEARCH

$5.05
+0.85% today

Updated 2026-06-04

Market cap
$8.16M
P/E ratio
P/S ratio
1,838.78x
EPS (TTM)
$-8.16
Dividend yield
52W range
$3 – $12
Volume
0.0M

ENDRA Life Sciences Inc (NDRA) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-408.67%
ROA
-122.30%
Debt/equity
0.26x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2014$559355.00$-2.18M53.67%-272.85%-389.89%
2015$1.41M$-2.28M52.75%-111.24%-161.64%
2016$515582.00$-2.78M54.25%-347.52%-538.30%
2017$351622.00$-5.38M50.86%-1,315.63%-1,529.19%
2018$6174.00$-9.80M100.00%-146,080.47%-158,669.60%
2019$0.00$-13.31M
2020$0.00$-11.73M
2021$0.00$-11.23M
2022$0.00$-13.18M
2023$0.00$-10.06M
2024$0.00$-11.51M
2025$0.00$-7.03M

Frequently asked questions

How much free cash flow does NDRA generate?

NDRA produced $-5.20M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is NDRA's balance sheet healthy?

NDRA holds $762365.00 in cash and equivalents against — in long-term debt, on $2.26M of shareholder equity. That debt is best read against the cash flow the business throws off each year.